Current Gastroenterology Reports

, Volume 2, Issue 1, pp 40–45 | Cite as

Hepatopulmonary syndrome

  • Michael B. Fallon
  • Gary A. Abrams
Article

Abstract

Hepatopulmonary syndrome is caused by intrapulmonary vasodilation that leads to abnormal arterial gas exchange in the setting of liver disease or portal hypertension. It is seen in up to 15% of cirrhotics and is an increasingly common indication for liver transplantation. Testing for the presence of oxygenation abnormalities and intrapulmonary vasodilation is needed to make the diagnosis. Excess production of nitric oxide in the lung contributes to pulmonary vasodilation and may be triggered by the release of mediators from the damaged liver. No medical therapies are established as effective, and liver transplantation is the only documented curative treatment.

References and Recommended Reading

  1. 1.
    Lange PA, Stoller JK: The hepatopulmonary syndrome. Ann Intern Med 1995, 122:521–529.PubMedGoogle Scholar
  2. 2.
    Rodriguez-Roison R, Agusti A, Roca J: The hepatopulmonary syndrome: new name, old complexities. Thorax 1992, 47:897–902.Google Scholar
  3. 3.
    Kennedy TC, Knudson RJ: Exercise aggregated hypoxemia and orthodeoxia in cirrhosis. Chest 1977, 72:305.PubMedGoogle Scholar
  4. 4.
    Abrams GA, Jaffe CC, Hoffer PB, et al.: Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995, 109:1283–1288.PubMedCrossRefGoogle Scholar
  5. 5.
    Dimand RJ, Heyman MB, Bass NM, et al.: Hepatopulmonary syndrome: response to hepatic transplantation [abstract]. Hepatology 1991, 141:55A.Google Scholar
  6. 6.
    Abrams G, Fallon M: The hepatopulmonary syndrome. Clin Liver Dis 1997, 1:185–200.PubMedCrossRefGoogle Scholar
  7. 7.
    Lee D, Lepler L: Severe intrapulmonary shunting associated with metastatic carcinoid. Chest 1999, 115:1203–1207.PubMedCrossRefGoogle Scholar
  8. 8.
    Sood G, Fallon MB, Niwas S, et al.: Utility of a dyspnea-fatigue index for screening liver transplant candidates for hepatopulmonary syndrome [abstract]. Hepatology 1998, 28:2319.Google Scholar
  9. 9.
    MacNee W, Buist T, Finlayson N, et al.: Multiple microscopic pulmonary arteriovenous connections in the lungs presenting as cyanosis. Thorax 1985, 40:316–318.PubMedGoogle Scholar
  10. 10.
    Abrams GA, Fallon MB, Nail C, et al.: Pulse oximetry: utility in detecting arterial hypoxemia in subjects with cirrhosis [Abstract]. Hepatology 1999, 30:A1099.Google Scholar
  11. 11.
    Park S, Beerman L, Gartner C, et al.: Echocardiographic findings before and after liver transplantation. Am J Cardiol 1985, 55:1373–1378.PubMedCrossRefGoogle Scholar
  12. 12.
    Krowka MJ, Cortese DA: Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. Hepatology 1990, 11:138–141.PubMedCrossRefGoogle Scholar
  13. 13.
    Hopkins WE, Waggoner BA, Barzilai B: Frequency and significance of intrapulmonary right-to-left shunting in end-stage hepatic disease. Am J Cardiol 1992, 70:516–519.PubMedCrossRefGoogle Scholar
  14. 14.
    Vedrinne JM, Duperret S, Bizollon T, et al.: Comparison of transesophageal and transthoracic contrast echocardiography for detection of an intrapulmonary shunt in liver disease. Chest 1997, 111:1236–1240. This work demonstrates that transesophageal echocardiography is more sensitive than transthoracic echocardiography in detecting intrapulmonary shunting due to vasodilation in liver disease.PubMedGoogle Scholar
  15. 15.
    Aller R, Moya JL, Moreira V, et al.: Diagnosis of hepatopulmonary syndrome with contrast transesophageal echocardiography: advantages over contrast transthoracic echocardiography. Dig Dis Sci 1999, 44:1243–1248.PubMedCrossRefGoogle Scholar
  16. 16.
    Genovesi MG, Tierney DF, Taplin GV, et al.: An intravenous radionuclide method to evaluate hypoxemia caused by abnormal alveolar vessels. Am Rev Respir Dis 1976, 114:59–65.PubMedGoogle Scholar
  17. 17.
    Wolfe JD, Tashkin DP, Holly FE, et al.: Hypoxemia of cirrhosis: detection of abnormal small pulmonary vascular channels by a quantitative radionuclide method. Am J Med 1977, 63:746–754.PubMedCrossRefGoogle Scholar
  18. 18.
    Abrams G, Nanda N, Dubovsky E, et al.: Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 1998, 114:305–310. This paper defines the utility of the radionuclide lung perfusion scan in the diagnosis of HPS. It indicates that this scan is less sensitive than contrast echocardiography for detecting intrapulmonary vasodilation, but is useful in detecting the presence of clinically significant HPS in the setting of underlying intrinsic pulmonary disease.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee KN, Lee HJ, Shin WW, et al.: Hypoxemia and liver cirrhosis (hepatopulmonary syndrome) in eight patients: comparison of the central and peripheral pulmonary vasculature. Radiology 1999, 211:549–553.PubMedGoogle Scholar
  20. 20.
    Sogni P, Moreau R, Gadano A, et al.: The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J Hepatol 1995, 23:218–224.PubMedCrossRefGoogle Scholar
  21. 21.
    Cremona G, Higenbottam TW, Mayoral V, et al.: Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. Eur Respir J 1995, 8:1883–1885.PubMedCrossRefGoogle Scholar
  22. 22.
    Rolla G, Bucca C, Brussino L: Methylene blue in the hepatopulmonary syndrome. N Engl J Med 1994, 331:1098.PubMedCrossRefGoogle Scholar
  23. 23.
    Rolla G, Brussino L, Colagrande P, et al.: Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1997, 26:842–847.PubMedCrossRefGoogle Scholar
  24. 24.
    Rolla G, Brussino L, Colagrande P, et al.: Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation. Ann Intern Med 1998, 129:375–378. This study and the companion work in reference 23 are the first large studies to provide evidence that excess pulmonary production of NO may be involved in the pathogenesis of human HPS.PubMedGoogle Scholar
  25. 25.
    Chang S-W, O'Hara N: Pulmonary circulatory dysfunction in rats with biliary cirrhosis. Am Rev Respir Dis 1992, 148:798–805.Google Scholar
  26. 26.
    Chang SW, Ohara N: Increased pulmonary vascular permeability in rats with biliary cirrhosis: role of thromboxane A2. Am J Physiol 1992, 264:L245-L252.Google Scholar
  27. 27.
    Chang SW, Ohara N: Chronic biliary obstruction induces pulmonary intravascular phagocytosis and endotoxin sensitivity in rats. J Clin Invest 1994, 94:2009–2019.PubMedCrossRefGoogle Scholar
  28. 28.
    Fallon MB, Abrams GA, McGrath JW, et al.: Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and the hepatopulmonary syndrome. Am J Physiol 1997, 272:G779-G784.PubMedGoogle Scholar
  29. 29.
    Fallon MB, Abrams GA, Luo B, et al.: The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997, 113:606–614. This study documents that an increase in eNOS protein in the pulmonary vasculature contributes to the development of intrapulmonary vasodilation in an animal model of HPS.PubMedCrossRefGoogle Scholar
  30. 30.
    Luo B, Abrams G, Fallon M: Endothelin-1 in the bile duct ligation model of hepatopulmonary syndrome: correlation with pulmonary dysfunction. J Hepatol 1998, 28:571–578.CrossRefGoogle Scholar
  31. 31.
    Pinzani M, Milani S, DeFranco R, et al.: Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996, 110:534–548.PubMedCrossRefGoogle Scholar
  32. 32.
    Rockey D, Fouassier L, Chung J, et al.: Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 1998, 27:472–480.PubMedCrossRefGoogle Scholar
  33. 33.
    Moore K, Wendon J, Frazer M, et al.: Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992, 327:1774–1777.PubMedCrossRefGoogle Scholar
  34. 34.
    Asbert M, Gines A, Gines P, et al.: Circulating levels of endothelin in cirrhosis. Gastroenterology 1993, 104:1485–1491.PubMedGoogle Scholar
  35. 35.
    Zhang M, Luo B, Chen S, et al.: Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. Am J Physiol 1999, 277:G944-G952. This study provides support for the unique hypothesis that overproduction of ET-1 in the damaged liver may be released into the pulmonary circulation and trigger endothelium-dependent vasodilation and HPS. It raises the possibility that other hepatic mediators may also contribute to pulmonary vasodilation and suggests novel targets for medical therapies.PubMedGoogle Scholar
  36. 36.
    Song JY, Choi JY, Ko JT, et al.: Long-term aspirin therapy for hepatopulmonary syndrome. Pediatrics 1996, 97:917–920.PubMedGoogle Scholar
  37. 37.
    Caldwell SH, Jeffers LJ, Narula OS, et al.: Ancient remedies revisited: does Allium sativum (garlic) palliate the hepatopulmonary syndrome? J Clin Gastroenterol 1992, 15:248–250.PubMedCrossRefGoogle Scholar
  38. 38.
    Abrams GA, Fallon MB: Treatment of hepatopulmonary syndrome with Allium sativum L. (garlic): a pilot trial. J Clin Gastroenterol 1998, 27:232–235.PubMedCrossRefGoogle Scholar
  39. 39.
    Reigler JL, Lang KA, Johnson SP, et al.: Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology 1995, 109:978–983.CrossRefGoogle Scholar
  40. 40.
    Selim KM, Akriviadis EA, Zuckerman E, et al.: Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol 1998, 93:455–458.PubMedCrossRefGoogle Scholar
  41. 41.
    Allgaier HP, Haag K, Ochs A, et al.: Hepatopulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS). J Hepatol 1995, 23:102–105.PubMedCrossRefGoogle Scholar
  42. 42.
    Corley DA, Scharschmidt B, Bass N, et al.: Lack of efficacy of TIPS for hepatopulmonary syndrome. Gastroenterology 1997, 113:728–731.PubMedCrossRefGoogle Scholar
  43. 43.
    Lange PA, Stoller JK: The hepatopulmonary syndrome: effect of liver transplantation. Clin Chest Med 1996, 17:115–123.PubMedCrossRefGoogle Scholar
  44. 44.
    Mandell MS, Groves BM, Duke J: Progressive plexogenic pulmonary hypertension following liver transplantation. Transplantation 1995, 59:1488–1490.PubMedCrossRefGoogle Scholar
  45. 45.
    Abrams GA, Rose K, Fallon MB, et al.: Hepatopulmonary syndrome and venous emboli causing intracerebral hemorrhages after liver transplantation: a case report. Transplantation 1999, 68:1–3.CrossRefGoogle Scholar
  46. 46.
    Scott V, Mira A, Kang Y, et al.: Reversibility of the hepatopulmonary syndrome by orthotopic liver transplantation. Transplant Proc 1993, 25:1787–1788.PubMedGoogle Scholar
  47. 47.
    Meyers C, Low L, Kaufman L, et al.: Trendelenburg positioning and continuous lateral rotation improve oxygenation in hepatopulmonary syndrome after liver transplantation. Liver Transpl Surg 1998, 6:510–512.CrossRefGoogle Scholar
  48. 48.
    Durand P, Baujard C, Grosse AL: Reversal of hypoxemia by inhaled nitric oxide in children with severe hepatopulmonary syndrome, type 1, during and after liver transplantation. Transplantation 1998, 65:437–439.PubMedCrossRefGoogle Scholar
  49. 49.
    Alexander J, Greenough A, Rela M, et al.: Nitric oxide treatment of severe hypoxemia after liver transplantation in hepatopulmonary syndrome. Liver Transpl Surg 1997, 1:54–55.CrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2000

Authors and Affiliations

  • Michael B. Fallon
    • 1
  • Gary A. Abrams
    • 1
  1. 1.Liver CenterUniversity Of Alabama at BirminghamBirminghamUSA

Personalised recommendations